This Hims & Hers Move Could Destroy Competitors
Key Points
The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers.
The fastest GLP-1 launch in history could be boosted by a wider distribution funnel.
This could bring growth back to Hims & Hers in 2026.
- These 10 stocks could mint the next wave of millionaires ›
Hims & Hers (NYSE: HIMS) has had a rough go of it in 2026, but a recent deal with Novo Nordisk (NYSE: NVO) may bring the company's operations back to life. The Wegovy pill is one of the products coming to Hims & Hers, and we now know details of what that launch will look like, and it could make this a high-growth stock by the end of 2026. In this video, I explain why this launch is so exciting.
*Stock prices used were end-of-day prices of March 18, 2026. The video was published on March 20, 2026.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 911%* — a market-crushing outperformance compared to 186% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of March 21, 2026.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Recommended Articles
